- Home
- CAI vs DVA Comparison
CAI vs DVA Comparison
Compare CAI & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAI
- DVA
- Stock Information
- Founded
- CAI 2008
- DVA 1994
- Country
- CAI United States
- DVA United States
- Employees
- CAI N/A
- DVA N/A
- Industry
- CAI Medical Specialities
- DVA Misc Health and Biotechnology Services
- Sector
- CAI Health Care
- DVA Health Care
- Exchange
- CAI Nasdaq
- DVA Nasdaq
- Market Cap
- CAI 9.4B
- DVA 9.4B
- IPO Year
- CAI 2025
- DVA 1995
- Fundamental
- Price
- CAI $32.94
- DVA $131.20
- Analyst Decision
- CAI Strong Buy
- DVA Hold
- Analyst Count
- CAI 6
- DVA 3
- Target Price
- CAI $35.50
- DVA $154.67
- AVG Volume (30 Days)
- CAI 518.8K
- DVA 846.5K
- Earning Date
- CAI 11-12-2025
- DVA 10-28-2025
- Dividend Yield
- CAI N/A
- DVA N/A
- EPS Growth
- CAI N/A
- DVA 8.72
- EPS
- CAI N/A
- DVA 10.20
- Revenue
- CAI $533,847,000.00
- DVA $13,161,328,000.00
- Revenue This Year
- CAI $64.66
- DVA $5.96
- Revenue Next Year
- CAI $45.81
- DVA $3.54
- P/E Ratio
- CAI N/A
- DVA $12.87
- Revenue Growth
- CAI 106.53
- DVA 5.09
- 52 Week Low
- CAI $25.40
- DVA $126.07
- 52 Week High
- CAI $42.50
- DVA $179.60
- Technical
- Relative Strength Index (RSI)
- CAI N/A
- DVA 43.55
- Support Level
- CAI N/A
- DVA $126.95
- Resistance Level
- CAI N/A
- DVA $131.34
- Average True Range (ATR)
- CAI 0.00
- DVA 2.73
- MACD
- CAI 0.00
- DVA -0.37
- Stochastic Oscillator
- CAI 0.00
- DVA 37.22
About CAI Caris Life Sciences Inc. Common Stock
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.